This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Aringer, M Articles by Smolen, J S Search for Related Content PubMed PubMed Citation Articles by Aringer, M Articles by Smolen, J S Social Bookmarking                         What's this?

Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention

Department of Rheumatology, Medical University of Vienna, Vienna, Austria

J S Smolen

Department of Rheumatology, Medical University of Vienna, Vienna, Austria, josef.smolen{at}wienkav.at

Systemic lupus erythematosus (SLE) is an autoantibody and immune complex mediated disease. However, it is the ensuing inflammatory process that leads to irreversibleorgandamage. In fact several murine models of SLE suggest that this inflammatory organ damage can be prevented even in the presence of autoantibodies. Given data from experimental models as well as from patients, proinflammatory cytokinesincluding tumour necrosis factor (TNF) alpha apparentlyplay a significant role in the inflammatory process, but may have immunoregulatory functions at the same time. Therefore, anti-TNF alpha therapy may constitute an interesting candidate approach for treating SLE inflammatory organ disease, but potentially at the cost of increased autoantibody formation. Clinical trials will be required to answer whether TNF alpha blockade fulfils this hope with an acceptable safety profile. Interferon (IFN)-g, interleukin(IL)-18, IL-6 and possiblyIL-1 are increasedin SLE and likewise involved in the inflammatory process. Specific therapeutic agents for blocking these cytokines should be available in the near future.

Key Words: cytokines • glomerulonephritis • inflammation • lupus • TNF

Lupus, Vol. 13, No. 5, 344-347 (2004)
DOI: 10.1191/0961203303lu1024oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L Zhu, X Yang, Y Ji, W Chen, W Guan, S. Zhou, and X Yu Up-regulated renal expression of TNF-{alpha} signalling adapter proteins in lupus glomerulonephritis Lupus, February 1, 2009; 18(2): 116 - 127. [Abstract] [PDF]

				M Aringer and J. Smolen TNF inhibition in SLE: where do we stand? Lupus, January 1, 2009; 18(1): 5 - 8. [PDF]

				J. Grisar, C. W. Steiner, M. Bonelli, T. Karonitsch, I. Schwarzinger, G. Weigel, G. Steiner, and J. S. Smolen Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells Rheumatology, October 1, 2008; 47(10): 1476 - 1483. [Abstract] [Full Text] [PDF]

				M. E. Monzon, D. Manzanares, N. Schmid, S. M. Casalino-Matsuda, and R. M. Forteza Hyaluronidase Expression and Activity Is Regulated by Pro-Inflammatory Cytokines in Human Airway Epithelial Cells Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 289 - 295. [Abstract] [Full Text] [PDF]

				Y-J. Lin, L. Wan, J.-C Sheu, C-M. Huang, C-W. Lin, Y-C. Lan, C-H. Lai, C-H. Hung, Y. Tsai, C-H. Tsai, et al. A/C polymorphism in the interleukin-18 coding region among Taiwanese systemic lupus erythematosus patients Lupus, February 1, 2008; 17(2): 124 - 127. [Abstract] [PDF]

				T. Horiuchi, C. Kiyohara, H. Tsukamoto, T. Sawabe, I. Furugo, S. Yoshizawa, A. Ueda, Y. Tada, T. Nakamura, Y. Kimoto, et al. A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis Ann Rheum Dis, March 1, 2007; 66(3): 320 - 324. [Abstract] [Full Text] [PDF]

				X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky Deficient CD4+CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus J. Immunol., February 15, 2007; 178(4): 2579 - 2588. [Abstract] [Full Text] [PDF]

				Y. Okabe, K. Kawane, S. Akira, T. Taniguchi, and S. Nagata Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation J. Exp. Med., November 21, 2005; 202(10): 1333 - 1339. [Abstract] [Full Text] [PDF]

				M. B. Stokes, K. Foster, G. S. Markowitz, F. Ebrahimi, W. Hines, D. Kaufman, B. Moore, D. Wolde, and V. D. D'Agati Development of glomerulonephritis during anti-TNF-{alpha} therapy for rheumatoid arthritis Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1400 - 1406. [Abstract] [Full Text] [PDF]

				C. K. Wong, L. C. W. Lit, L. S. Tam, E. K. Li, and C. W. K. Lam Elevation of plasma osteopontin concentration is correlated with disease activity in patients with systemic lupus erythematosus Rheumatology, May 1, 2005; 44(5): 602 - 606. [Abstract] [Full Text] [PDF]

				S Vasoo and G R. Hughes Theory, targets and therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 181 - 188. [Abstract] [PDF]

				J S Smolen, G Steiner, and M Aringer Anti-cytokine therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 189 - 191. [Abstract] [PDF]